Hoeller Ulrike, Borgmann Kerstin, Bonacker Michael, Kuhlmey Antje, Bajrovic Amira, Jung Horst, Alberti Winfried, Dikomey Ekkehard
Department of Radiotherapy and Radiooncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Radiother Oncol. 2003 Nov;69(2):137-44. doi: 10.1016/j.radonc.2003.10.001.
To analyse the relationship of individual cellular radiosensitivity and fibrosis after breast conserving therapy. A new model was used describing the percentage of patients developing fibrosis per year and per patient at risk.
In a retrospective study, 86 patients were included, who had undergone breast conserving surgery and irradiation of the breast with a median dose of 55 Gy (54-55 Gy) given at 2.5 Gy/fraction (n=57) or 2 Gy/fraction (n=29). Median age was 62 years (range 44-86) and median follow-up was 7.5 years (range 5-17). Patients were examined for fibrosis according to the LENT/SOMA score. For analysis, fibrosis was classified as grade 0 and grade 1 (G0-1) or present grade 2 and grade 3 (G2-3). The time to complete development of fibrosis was determined by analysis of yearly mammograms. Individual cellular radiosensitivity was determined by scoring lethal chromosomal aberrations in in vitro irradiated (6 Gy) lymphocytes using metaphase technique. Patients with low/intermediate cellular radiosensitivity were compared with patients with high cellular radiosensitivity using actuarial methods.
Ten patients developed fibrosis at 1-8 years after radiotherapy. Individual cellular radiosensitivity was described by normal distribution of lethal chromosomal aberrations, the average was 5.47 lethal aberrations per cell (standard deviation (SD) 0.71). Cellular radiosensitivity was defined as low/intermediate (< or =6.18 lethal aberrations) in 73 patients and high (>6.18 lethal aberrations; mean+SD) in 13 patients. In both groups, the actuarial rate of fibrosis-free patients decreased exponentially with time after radiotherapy. Patients with high cellular radiosensitivity showed a 2.3-fold higher annual rate for fibrosis than patients with intermediate and low radiosensitivity (3.6 versus 1.6% per year).
In breast cancer patients, high individual cellular radiosensitivity as determined by the number of lethal chromosome aberrations in in vitro irradiated lymphocytes might be associated with an enhanced annual rate of fibrosis.
分析保乳治疗后个体细胞放射敏感性与纤维化之间的关系。采用一种新模型来描述每年以及每位有风险患者发生纤维化的百分比。
在一项回顾性研究中,纳入了86例患者,这些患者均接受了保乳手术及乳腺放疗,中位剂量为55 Gy(54 - 55 Gy),分割剂量为2.5 Gy/次(n = 57)或2 Gy/次(n = 29)。中位年龄为62岁(范围44 - 86岁),中位随访时间为7.5年(范围5 - 17年)。根据LENT/SOMA评分对患者进行纤维化检查。为进行分析,将纤维化分为0级和1级(G0 - 1)或存在2级和3级(G2 - 3)。通过分析每年的乳房X线照片确定纤维化完全发展的时间。采用中期技术对体外照射(6 Gy)淋巴细胞中的致死性染色体畸变进行评分,以确定个体细胞放射敏感性。使用精算方法比较低/中等细胞放射敏感性患者与高细胞放射敏感性患者。
10例患者在放疗后1 - 8年出现纤维化。个体细胞放射敏感性通过致死性染色体畸变的正态分布来描述,平均每个细胞有5.47个致死性畸变(标准差(SD)0.71)。73例患者的细胞放射敏感性被定义为低/中等(≤6.18个致死性畸变),13例患者为高(>6.18个致死性畸变;均值 + SD)。在两组中,放疗后无纤维化患者精算率均随时间呈指数下降。高细胞放射敏感性患者的纤维化年发生率比中低放射敏感性患者高2.3倍(每年3.6%对1.6%)。
在乳腺癌患者中,通过体外照射淋巴细胞中致死性染色体畸变数量确定高个体细胞放射敏感性可能与纤维化年发生率增加有关。